Furthermore, we showed previously that MET exon 14–altered NSCLCs had low TMB and poor outcomes with immunotherapy.17 Finally, an ongoing global registry (Immunotarget) and independent series have shown similarly low response rates and short median PFS with single-agent immune checkpoint inhibition in lung cancers with oncogenic drivers.18 Immunotarget had 16 patients in the RET-rearranged cohort and reported a response rate of 6% and median PFS of 2.1 months, comparable to the findings in our study. The gene discussed is MET; the disease is lung cancer.